Abstract
Standard doses of H2-receptor antagonists are usually effective in milder forms of reflux oesophagitis, but these lower doses induce relatively low healing rates in more severe forms of the disease. In the patients with severe reflux oesophagitis, prokinetic or mucosa-protecting agents do not offer better results, whereas a combination of standard doses of H2-receptor antagonists with prokinetic or mucosa-protecting agents results in no or only marginally better results than obtained with H2-receptor antagonist mono-therapy. Several studies have shown that insufficient inhibition of gastric acid secretion is the major reason for the low healing rates obtained with standard doses of H2-receptor antagonists. It has recently been shown that higher doses of ranitidine increase the time the oesophageal pH is above 4 and induce higher healing rates in patients with severe reflux oesophagitis. Therefore, we now have three therapeutic options for patients with severe reflux oesophagitis: first, higher doses of hi...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have